Michael D. Clayman - Jun 21, 2021 Form 4 Insider Report for Flexion Therapeutics Inc (FLXN)

Role
President and CEO, Director
Signature
/s/ Mark S. Levine, Attorney-in-Fact
Stock symbol
FLXN
Transactions as of
Jun 21, 2021
Transactions value $
$13,226
Form type
4
Date filed
6/28/2021, 06:04 PM
Next filing
Jul 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FLXN Common Stock Award $13.2K +1.7K +0.49% $7.78 349K Jun 21, 2021 Direct F1
holding FLXN Common Stock 374K Jun 21, 2021 By the Michael D.Clayman 2006 Revocable Trust
holding FLXN Common Stock 24.6K Jun 21, 2021 By the Michael D. Clayman Irrevocable Trust
holding FLXN Common Stock 389K Jun 21, 2021 By Versant Development Fund III, LLC F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 4 is being filed voluntarily to report the acquisition of 1,700 shares by the Reporting Person on June 21, 2021, pursuant to the Issuer's Employee Stock Purchase Plan.
F2 Shares held by Versant Development Fund III, LLC. The Reporting Person is a manager and minority member of Versant Development Fund III, LLC. The Reporting Person disclaims any beneficial ownership of the shares held by Versant Development Fund III, LLC except to the extent of his pecuniary interest in these shares.